A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors

BACKGROUND: Carboxyamido-triazole (CAI) is a calcium influx inhibitor with anti-angiogenic and anti-invasive properties and stabilizes tumor progression in patients. We hypothesized daily oral micronized CAI with q3 week paclitaxel would be well-tolerated and active. RESULTS: Twenty-nine heavily pre...

Full description

Saved in:
Bibliographic Details
Main Authors: Azad, Nilofer, Perroy, Alyssa, Gardner, Erin, Imamura, Chiyo K., Graves, Cynthia, Sarosy, Gisele A., Minasian, Lori, Kotz, Herbert, Raggio, Miranda, Figg, William D., Kohn, Elise C.
Format: Artigo
Language:Inglês
Published: 2009
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3104675/
https://ncbi.nlm.nih.gov/pubmed/19738417
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items